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A B S T R A C T
Tumor necrosis factor α (TNFα) inhibitors are highly effective and a therapeutic choice for several inflammatory
diseases. Their broad and long-term use is associated with a growing number of paradoxical autoimmune events
including demyelinating lesions of the central nervous system (CNS). We report and discuss a case of neuro-
myelitis optica spectrum disorder (NMOSD) with positive myelin oligodendrocyte glycoprotein antibodies
(MOG-IgG1) following anti-TNFα therapy for a pustular psoriasis.
1. Background
Tumor necrosis factor α (TNFα) blockers are highly effective and a
therapeutic choice for several inflammatory diseases (e.g. rheumatoid
arthritis and psoriasis). Today, five anti-TNFα inhibitors have been
approved for clinical use: etanercept (soluble TNF receptor 2), in-
fliximab, adalimumab, golimumab (IgG monoclonal antibodies) and
certolizumab (PEGylated Fab1 fragment of an IgG monoclonal anti-
body).
The widespread and long-term use of TNF-targeted therapies is as-
sociated with a growing number of paradoxical induced autoimmune
processes, including both systemic (lupus, vasculitis, sarcoidosis, anti-
phospholipid syndrome) and organ–specific diseases (interstitial lung
disease, autoimmune hepatitis, uveitis, optic neuritis, peripheral neu-
ropathies, multiple sclerosis, multiple sclerosis-like diseases). Although
the prevalence of demyelinating events of the central nervous system
(CNS) ranged between 0.05–0.2% in clinical and post-marketing stu-
dies, over 800 cases have been identified to date (Retamozo et al.,
2017). Typically it includes isolated optic neuritis and transverse
myelitis occurring between one month and one year after anti-TNFα
initiation. In the majority of cases, the disease will not relapse after TNF
inhibitor's discontinuation, however a subset of patient will develop a
relapsing-remitting course despite discontinuation of the offending
agent.
We report and discuss a case of neuromyelitis optica spectrum dis-
order (NMOSD) with positive myelin oligodendrocyte glycoprotein
antibodies (MOG-IgG1) following anti-TNFα therapy for a pustular
psoriasis.
2. Case presentation
A 40 year-old man with a ten-year history of pustular psoriasis was
examined in March 2015 after developing right upper limb paraesthesia
and Lhermitte's phenomenon. Except bilateral exaggerated knee and
ankle reflexes, the neurological exam was unremarkable.
This patient had been treated for ten years with several im-
munosuppressive drugs for a moderate psoriasis, including aza-
thioprine, methotrexate, etanercept and more recently adalimumab.
Etanercept – 50mg once weekly – had been administered from April
2012 to June 2013. Because of poor effectiveness, it was switched to
adalimumab after three months washout. Adalimumab – 40mg every
other week – had been started 18 months before the first neurological
manifestations.
Brain MRI was normal but spinal cord MRI revealed a longitudinally
extensive transverse myelitis (LETM) at the bulbo-medullar junction
with Gadolinium® enhancement (Fig. 1(a) and (b)). The available ac-
cumulated laboratory data did not provide evidence for infectious or
systemic autoimmune myelitis. Autoimmune screening was normal (C-
reactive protein, sedimentation rate, anti-thyroperoxidase antibodies,
anti-neuronal antibodies, anti-neutrophil cytoplasmic antibodies, anti-
nuclear antibodies, complement levels, anti-cardiolipin antibodies,
anti-beta 2 glycoprotein antibodies) and plasma AQP4-IgG were not
detected. Viral (Cytomegalovirus, Epstein-Barr Virus, Varicella-Zoster
Virus, Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency
Virus), parasitic (Toxoplasma) and bacterial (Borrelia, Syphilis, Myco-
plasma Pneumoniae, Chlamydia Pneumoniae) serologies were negative
as well as QuantiFERON®-TB test. Cerebral spinal fluid (CSF) analysis
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showed lymphocytic pleocytosis (25 cells/μL; 70% lymphocytes),
slightly increased total protein (680mg/L), normal glucose level and
IgG index. No oligoclonal bands were detected. The whole body FDG
PET-CT was normal.
Intravenous administration of high-dose steroids resulted in a
complete clinical recovery within 2 weeks. A repeat MRI performed
after 3 months revealed a thorough regression of bulbo-medullar lesion
on T2 sequence and no residual Gadolinium® enhancement (Fig. 1(c)).
Adalimumab was discontinued and he did not receive any other treat-
ment of psoriasis except photodynamic therapy during minor relapses.
The clinical and radiological follow-up conducted twice a year was
unremarkable. However, seventeen months after the first demyeli-
nating event, the patient presented with a painful left eye with blurred
vision. Ophthalmologic examination confirmed an optic neuritis with
slight papillary edema. Brain MRI showed a T2 hyper-intense signal in
the intra-orbital part of the left optic nerve (Fig. 1(d)) with a discrete
enhancement. Spinal cord MRI remained unchanged. We repeated the
autoimmune screening. AQPA4-IgG were absent but newly described
MOG-IgG1 positive. Testing for the presence of serum MOG-IgG1 was
performed in the Autoimmune Neurology Laboratory in Oxford, using a
cell-based assay (Waters et al., 2015). Again the patient was treated
with IV steroids and rapidly recovered. Mycophenolate, at a dosage of
1 g twice daily, was started. The persistence of MOG-IgG1 after one year
on immunosuppressive drug warranted continuing this treatment. Since
then, the patient did not present any neurological manifestation.
3. Discussion
We report the occurrence of neurologic symptoms following TNFα
inhibitors and other non-selective immunosuppressive treatments for
psorias. Clinical and radiological features are consistent with demyeli-
nating disease and patient met diagnostic criteria for NMOSD with
positive MOG-antibodies (Wingerchuk et al., 2015). NMOSD has never
been reported in this context neither positive MOG-IgG1. Im-
munosuppressants such as azathioprine, mycophenolate and rituximab
are recommended to treat MOG-antibodies related disorders (Jarius
et al., 2016; Ramanathan et al., 2016). However data regarding dura-
tion, efficacy and type of immunotherapy are still limited. Although
patient can become antibody-negative and remain relapse free off
therapy, the duration of immunosuppression after the disease onset
does not seem to predict the antibody status (Jurynczyk et al., 2017).
Several factors suggest an etiological role for TNFα blockers in the
development of demyelinating disorders. First, disease is temporally
associated with initiation of therapy. Second, the symptomatology is
suggestive of an antigen-mediated hypersensitivity process. Last, the
disease most often resolves after discontinuation of therapy and/or a
positive rechallenge phenomenon (reappearance or worsening of
symptoms on re-exposure to the agent) is observed. However, it is still
unclear whether these events are coincidental, revealed or triggered by
the TNFα blockers. Even more elusive remain the underlying patho-
genic mechanisms regarding the pleiotropic functions of TNFα and
their contradictory effects, particularly in the CNS. TNFα and its re-
ceptors (TNRF1 and TNRF2) can either promote neuroinflammation
and secondary neuronal damage, or exert neuroprotective properties
under pathological conditions (Probert, 2015). However elevated TNFα
production was observed in patients and animal models of MS, TNFα
blockers failed to produce any beneficial effects in MS and even led to
worsening the disease (The Lenercept Multiple Sclerosis Study
Group, 1999). Interestingly, systemic administration of anti-TNF-α
enhances antigen presenting cell function, decreases apoptosis of po-
tentially autoreactive T-cells and induce the production of proin-
flammatory cytokines. As a consequence, prolonged exposure to anti-
TNF-α likely promotes the activation and survival of potentially auto-
reactive T-cells in the periphery, which might subsequently penetrate
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4. Conclusion
Anti-TNFα therapies revolutionized the management of disabling
inflammatory diseases but autoimmune diseases may be associated with
their use. Especially, an increasing number of CNS demyelinating dis-
orders have been reported in this context and some of them have
evolved into chronic relapsing condition after discontinuation of the
therapy. MOG-antibodies related disorders are so rare, that coincidental
co-occurrence cannot be ruled out in this specific case. Nevertheless we
propose a systematic screening of CNS side effects by regular clinical
follow up during therapy and CNS MRI before its initiation. Treatment
should be discontinued in the presence of any documented neurological
manifestations. More generally, the risks of secondary autoimmune
diseases should be considered when using treatments with potential
complex effects on the immune system.
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